Reply to “A better interpretation of data regarding the opioid switching to methadone”-Reference-Cited by-同舟云学术

Reply to “A better interpretation of data regarding the opioid switching to methadone”

Published:2023-06-07 Issue:1 Volume:22 Page:
ISSN:1472-684X
Container-title:BMC Palliative Care
language:en
Short-container-title:BMC Palliat Care

Author:

Ding Haiying,Song Yu,Xin Wenxiu,Sun Jiao,Zhong Like,Zhou Qinfei,He Chaoneng,Gong Liyan,Fang Luo

Abstract

AbstractIn our article ?Methadone switching for refractory cancer pain’ (BMC palliative care, 2022) we explore the efficacy, safety and economics of methadone in treatment of patients with refractory cancer pain in China. Professor Mercadante provided a better interpretation of data regarding the opioid switching to methadone in the Matters Arising. In this article, we answered the questions in Mercadante et al.’s comments one by one.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

https://link.springer.com/content/pdf/10.1186/s12904-023-01162-z.pdf

Reference13 articles.

1. Ding H, Song Y, Xin W, Sun J, Zhong L, Zhou Q, et al. Methadone switching for refractory cancer pain. BMC Palliat Care. 2022;21(1):191.

2. Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241–8.

3. Kreutzwiser D, Tawfic QA. Methadone for Pain Management: a pharmacotherapeutic review. CNS Drugs. 2020;34(8):827–39.

4. Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev. 2017;2(2):Cd003971.

5. Yang J, He MM, Niu W, Wrighton SA, Li L, Liu Y, et al. Metabolic capabilities of cytochrome P450 enzymes in chinese liver microsomes compared with those in caucasian liver microsomes. Br J Clin Pharmacol. 2012;73(2):268–84.